News Release: Hemedex, Inc. Announces VP of Technology

Posted by on Jul 11, 2013 in News Releases

News Release: Hemedex, Inc. Announces VP of Technology

CAMBRIDGE, Mass. (July 15, 2013) – Hemedex, Inc., a Cambridge-based medical device company, announced the recent hire of Scott D. Greenwald, Ph.D., as Vice President of Technology. Dr. Greenwald joined Hemedex from Covidien where he served for three years as Senior Director of Advanced Research for the Respiratory and Patient Monitoring Business Unit. Previously, he served Aspect Medical Systems for 17 years, most recently as Vice President of Research.

Dr. Greenwald brings over 20 years of experience managing innovative, and early-phase development of novel medical devices, most notably the Bispectral Index (BIS) developed by Aspect Medical Systems. Dr. Greenwald has expertise in biomedical signal processing, analytics and outcomes research, and is a significant individual contributor as co-inventor of three novel patient monitoring technologies (BIS, CVI, and ATR), co-author of eight US Patents, and co-author of over 100 peer-reviewed publications that support the development, clinical utility, and benefits of the technologies he helped to develop.

“Dr. Greenwald’s creativity and practical experience complements our team well,” said H. Frederick Bowman, Ph.D., President, CEO & Chairman of Hemedex, Inc. “As the market continues to broadly adopt our current product line, he will lead the development of novel applications utilizing our platform technology to sustain the long-term, robust growth of the business.”

Dr. Greenwald received a B.S. in Engineering jointly from the departments of Biomedical and Electrical Engineering from Duke University, a S.M. in Electrical Engineering and Computer Science from MIT, and a Ph.D. in Medical Engineering from MIT via the Harvard-MIT Division of Health Sciences and Technology.

About Hemedex, Inc.:

Hemedex, Inc. manufactures patient monitoring technology, the Bowman Perfusion Monitor®, for quantifying tissue blood flow. The Company’s patented technology provides clinicians with a powerful tool, which can provide an early warning of compromised blood flow and help target appropriate therapies rapidly and accurately. Data from the Bowman Perfusion Monitor helps guide physicians in implementing effective treatments quickly, creating the potential to improve patient outcomes and lower costs. Hemedex’s technology addresses unmet needs in many clinical areas such as neurocritical care (e.g., TBI, SAH), neurosurgery (e.g., TAO, EC-IC Bypass, Moya Moya), reconstructive surgery and organ transplantation, among others.  For more information, visit


Communications Team
Hemedex Inc.
617 577 1759 X 46